Why Gilead Sciences Might Not Make an Oncology Acquisition
Is Gilead Sciences (NASDAQ: GILD) backing away from its plans to acquire a smaller biotech focusing on oncology? That could be the case. Gilead CEO John Milligan reportedly told Leerink analyst Geoffrey Porges that the company "might end up doing nothing in oncology."
Just a few months ago, Milligan and other Gilead executives were openly talking about the possibility of an acquisition to bolster its oncology portfolio. What's changed? And what could this mean for Gilead?
Image source: Getty Images.
Source: Fool.com
Vertex Pharmaceuticals Inc. Aktie
436,20 €
0,86 %
Und Vertex Pharmaceuticals Inc. steht derzeit mit 58 Buy-Einschätzungen und 2 Sell-Einschätzungen bei unserer Community gut im Kurs.
Das Kursziel von 459 € für Vertex Pharmaceuticals Inc. weist auf eine leichte Verbesserung gegenüber dem aktuellen Kurs von 436.2 € hin.
